References
- Andes D, Craig WA. (2007). In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 51:1633–42
- Baldoni D, Furustrand Tafin U, Aeppli S, et al. (2013). Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Int J Antimicrob Agents 42:220–5
- Bradley JS, Puttagunta S, Rubino CM, et al. (2015). Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age. Pediatr Infect Dis J 34:748–52
- Buckwalter M, Dowell JA. (2005). Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 45:1279–87
- Dorr MB, Jabes D, Cavaleri M, et al. (2005). Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 55(Suppl. 2):ii25–30
- Dowell JA, Goldstein BP, Buckwalter M, et al. (2008). Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 48:1063–8
- Esposito S, Noviello S, Leone S. (2015). Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Infez Med 23:313–17
- Goldstein BP, Draghi DC, Sheehan DJ, et al. (2007). Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51:1150–4
- Klinker KP, Borgert SJ. (2015). Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther 37:2619–36
- Leighton A, Gottlieb AB, Dorr MB, et al. (2004). Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48:940–5
- Lin G, Credito K, Ednie LM, Appelbaum PC. (2005). Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 49:770–2
- Marbury T, Dowell JA, Seltzer E, Buckwalter M. (2009). Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 49:465–76
- Nicolau DP, Sun HK, Seltzer E, et al. (2007). Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60:681–4
- Scoble PJ, Owens RC Jr, Puttagunta S, et al. (2015). Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects. Clin Drug Investig 35:785–93
- Srinivas NR. (2015a). Differences in the prediction of area under the curve for a protease inhibitor using trough versus peak concentration: assessment using published pharmacokinetic data for indinavir. Am J Ther. [Epub ahead of print]. doi: 10.1097/MJT.0000000000000294
- Srinivas NR. (2015b). Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharm Drug Dispos 36:575–86
- Srinivas NR. (2016a). Limited sampling strategy for the prediction of area under the curve (AUC) of statins: reliability of a single time point for AUC prediction for pravastatin and simvastatin. Drug Res (Stuttg) 66:82–93
- Srinivas NR. (2016b). Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy. Am J Health Syst Pharm 73:376–85
- Srinivas NR. (2016c). Prediction of area under the curve for a P-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Dev Ind Pharm 42:945–57
- Srinivas NR, Syed M. (2016a). Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: superiority of Ctrough- over Cmax-derived linear regression models. Drugs R D 16:69–79
- Srinivas NR, Syed M. (2016b). Intranasal pharmacokinetic fata for triptans such as sumatriptan and zolmitriptan can render area under the curve (AUC) predictions for the oral route: strategy development and application. J Pain Palliat Care Pharmacother 30:13–24
- Stewart PS, Costerton JW. (2001). Antibiotic resistance of bacteria in biofilms. Lancet 358:135–8
- Trampuz A, Widmer AF. (2006). Infections associated with orthopedic implants. Curr Opin Infect Dis 19:349–56
- Van Bambeke F. (2015). Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review. Drugs 75:2073–95
- Zhanel GG, Calic D, Schweizer F, et al. (2010). New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:859–86